Healthcare resource utilization data from 774,968 adults with type 2 diabetes revealed that GLP-1 RA use was associated with significant reductions in outpatient hospital visits for depression (IRR: 0.96; 95% CI: 0.95–0.98) and office visits for both depression (IRR: 0.87; 95% CI: 0.82–0.92) and anxiety (IRR: 0.85; 95% CI: 0.81–0.90) compared to DPP-4 inhibitors [200]. The gene discussed is GLP1R; the disease is depressive symptom measurement.